Form 4: Vor Biopharma CEO Robert Ang Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Vor Biopharma CEO Robert Ang disposed of 2,751 shares of common stock on November 1, 2024, to cover tax withholding obligations related to the settlement of restricted stock units.
Summary
- On November 1, 2024, Robert Ang, the President and CEO of Vor Biopharma Inc., disposed of 2,751 shares of common stock.
- The transaction was executed to satisfy tax withholding obligations associated with the settlement of restricted stock units.
- Following the transaction, Ang directly owns 789,848 shares of Vor Biopharma Inc.
- The sale was conducted at a price of $0.8 per share.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares to cover taxes) and doesn't indicate any significant positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This transaction appears to be a routine sale to cover tax obligations.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 11/01/2024 | Date of transaction: Robert Ang disposed of 2,751 shares of Vor Biopharma Inc. |
| 11/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.